HIGHLIGHTS
- who: PROTACs et al. from the Department of Surgical, Oncological, and Oral Sciences, Section of Medical Oncology, Uiniversity of Palermo, Palermo, Italy, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Turin, Italy, The Fifth Affiliated Hospital of have published the research work: PROTACs: The Future of Leukemia Therapeutics, in the Journal: (JOURNAL)
- what: The focus of this review will be on PROTACs designed as a potential anticancer treatment, particularly against leukemia.
- how: Showed that while the noncovalent PROTACs was the most effective the reversible PROTAC (RC-3) still showed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.